Fernandez-De-Los-Reyes, Irene
Gomez-Dorronsoro, Marisa
Monreal-Santesteban, Iñaki
Fernandez-Fernandez, Agustín
Fraga, Mario
Azcue, Pablo
Alonso, Laura
Fernandez-Marlasca, Beatriz
Suarez, Javier
Cordoba-Iturriagagoitia, Alicia
Guerrero-Setas, David
Funding for this research was provided by:
Universidad Pública de Navarra
Article History
Received: 9 September 2023
Accepted: 19 November 2023
First Online: 13 December 2023
Declarations
:
: The study was approved by the Regional Clinical Research Ethics Committee (CEIC) Pyto2017/51 Cod. MOL_CRC, 15/05/2018. Patient consent was waived due to usage of stored tumor samples for research purposes in compliance with the current Spanish and European Union legislation (resolution 1387/2017 (08/11) and resolution 193/2018 (06/03) of the Navarra Health Service-Osasunbidea).
: Not applicable.
: P.A. is an employee of AstraZeneca AG, although there were no affiliations or financial involvement with this or any other organization or entity, with financial or scientific interest, or with the subject matter or materials discussed in the manuscript. All other authors declare no potential conflicts of interest.